MedTrace Logo

A Study With NLY01 in Subjects With Type 2 Diabetes

NCT04159766 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-02

No results posted yet for this study

Summary

This is a Phase 2a study designed to assess the effect of NLY01 in patients with type 2 diabetes. Patients will be monitored for safety, pharmacokinetics, and pharmacodynamic effects on glycemic control.

Conditions

  • Type2 Diabetes
  • Diabetes Mellitus, Type 2

Interventions

DRUG

NLY01

NLY01, a PEGylated form of the anti-diabetic peptide exenatide

DRUG

Placebo

normal saline

Sponsors & Collaborators

  • Neuraly, Inc.

    lead INDUSTRY

Principal Investigators

  • Dan Lee · Neuraly, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-16
Primary Completion
2020-12-04
Completion
2020-12-04

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04159766 on ClinicalTrials.gov